Healthcare Providers and Services
Company Overview of The General Hospital Corporation
The General Hospital Corporation operates as a general hospital in Boston. It offers services in the areas of allergy and immunology, blood, cancer, circulatory, dermatology, digestive, heart, infectious diseases, kidneys, lung, obstetrics and gynecology, psychiatry, rheumatology, surgery, and urology; bones, muscles, and joints; brain, spine, and nervous system; endocrine, diabetes, and metabolism; and mouth, teeth, and face. The company also provides patient and family support services, such as billing and insurance, child care, emotional and support programs, executive health, international patient, medical interpreter, medical records, mind body medicine, nursing, nutrition, patient and ...
55 Fruit Street
Boston, MA 02114
Founded in 1811
Key Executives for The General Hospital Corporation
Chief of Dermatology Service, Director of Melanoma Program for Mgh Cancer Center and Director of Cutaneous Biology Research Center
Chairman of the Chiefs' Council
Chief of Medical Services and Physician-in-Chief
Compensation as of Fiscal Year 2014.
The General Hospital Corporation Key Developments
Infraredx Announces Research Collaboration with Massachusetts General Hospital to Explore New Generation of Cardiovascular Imaging Devices
Dec 16 14
Infraredx, Inc. announced a collaboration with Massachusetts General Hospital (MGH) and coronary imaging researcher, Gary Tearney, M.D., Ph.D., professor of pathology at Harvard Medical School, Mike and Sue Hazard Family MGH Research Scholar, and founder of the Tearney Lab at the Wellman Center for Photomedicine at MGH. The TVC Imaging System is the only FDA-cleared technology capable of rapidly, specifically and reliably identifying lipid core plaques, which are known to complicate stenting procedures and are suspected to be the vulnerable plaques that cause most heart attacks, using NIRS, and providing vessel structure information using intravascular ultrasound (IVUS). The multi-year collaboration will focus on research and development of new and combination technologies that aim to provide enhanced information about coronary disease in patients.
RetroSense Therapeutics Signs License Agreement with Massachusetts General Hospital, Expanding its Optogenetics Intellectual Property Portfolio
Nov 17 14
RetroSense Therapeutics, LLC announced the signing of a license agreement for exclusive, worldwide rights to Massachusetts General Hospital's patent application entitled "Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration". Licensing provides RetroSense with worldwide access to key intellectual property which reinforces the Company's dominant position in optogenetics for vision restoration. The licensed intellectual property is based on methods for restoring or improving vision using optogenetic approaches. The patent is based on research conducted by Richard Masland, Ph.D., director of the Cellular Neurobiology Laboratory in the MGH Department of Neurosurgery.
Massachusetts General Hospital and Massachusetts Institute of Technology Form Strategic Partnership to Address Major Challenges in Clinical Medicine
Oct 15 14
Massachusetts General Hospital and Massachusetts Institute of Technology formed a strategic partnership to address major challenges in clinical medicine. A novel partnership between Massachusetts General Hospital (MGH) and Massachusetts Institute of Technology (MIT) is addressing three major challenges in clinical medicine improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies. The new partnership will follow the example set by the Ragon Institute of MGH, MIT and Harvard, which was founded in 2009 to find new ways of preventing and curing human disease through harnessing the power of the immune system, with an initial focus on the need for an effective vaccine against AIDS. Over the past five years, MIT engineers and scientists, MGH clinicians and investigators, and collaborators from institutions in the U.S. and around the world have made important progress towards solving one of the scientific and medical challenges of time. Under the new partnership, MGH and MIT have committed to providing up to $3 million over a two-year period to fund research projects addressing three Grand Challenges in diagnostics, infectious/autoimmune diseases and neurosciences. Teams applying for the grants must include a principal investigator from each institution, and projects must have the potential to generate results that could lead to further funding from external sources within a year or two. For the first of the challenges, six grants are being funded two major grants covering two years of funding and four smaller, one-year grants that will be eligible for renewal.
Similar Private Companies By Industry
Recent Private Companies Transactions